<DOC>
	<DOCNO>NCT00822354</DOCNO>
	<brief_summary>The investigator propose tadalafil increase digital blood flow improve symptom sign secondary Raynaud 's phenomenon .</brief_summary>
	<brief_title>Tadalafil Treatment Raynaud 's</brief_title>
	<detailed_description>The primary goal study decrease frequency , duration severity vasospastic attack patient secondary Raynaud 's . The secondary goal document increase blood flow lessen capillary dysfunction patient . Both goal achieve use course treatment Tadalafil.We anticipate decrease frequency , duration severity Raynaud 's attack . Improved digital blood flow digital blood pressure , decrease digital capillary dysfunction .</detailed_description>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>active Raynaud 's Phenomenon stable disease medication requirement previous 2 month subject willing able participate study assessment ability understand sign inform consent age 18 65 , sex diagnosis diffuse limit cutaneous sclerosis , MCTD use American College Rheumatology criterion uncontrolled HTN , DM , unstable disease , angina use oral nitrate smoke , active alcoholism , drug abuse within 5 year abnormal renal function ulnar arterial occlusive disease show positive Allen Test Pregnant breast feed consider preg . next 4 month past present major psych . illness allergy sensitivity tadalafil subject unable understand protocol give inform consent part . another study trial within 30 day take sildenafil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Secondary Raynaud 's Phenomenon</keyword>
</DOC>